Skip to content

Improving Status Epilepticus Treatment Times

Quality Improvement in Time to Treatment of Status Epilepticus

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06194747
Acronym
QuITT-SE
Enrollment
450
Registered
2024-01-08
Start date
2024-02-01
Completion date
2027-03-31
Last updated
2026-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Status Epilepticus

Keywords

Status Epilepticus, Quality Improvement, Interventions

Brief summary

This is a stepped-wedge cluster randomized effectiveness-implementation hybrid study aimed at determining the effect of dissemination of a QI bundle on the time to treatment of SE among hospitalized, non-critically ill children. The primary study endpoint is to decrease the time from the SE diagnosis to treatment with the first dose of a benzodiazepine (BZD) as measured during hospitalization, which will decrease chances of morbidity and mortality.

Detailed description

The overall study design is a stepped-wedge cluster randomized trial. A stepped-wedge is a unidirectional crossover design in which clusters switch treatments at different time points, enabling statistically rigorous assessment of interventions while reducing ethical and resource limitations for quality improvement studies.\[1\] Seven centers will be randomly assigned to implement the QI bundle at staggered 1-month intervals after a baseline period. Only the timing of the dissemination visit will be randomized; all sites will receive the same materials and perform the same activities (e.g. focus group, process map development, simulations). This study is an effectiveness-implementation hybrid study. The effectiveness-implementation hybrid design is ideal for assessing both clinical interventions and implementation.17 Importantly, our interventions have strong face-validity, are evidence-based, low-risk and low-cost. For instance, the price to change BZD formulations is nominal (\ $1 per dose), and other QI bundle interventions are primarily focused on frontline staff process changes. While testing the effect of the QI bundle on time to BZD treatment, we will utilize this framework and mixed methods analysis to measure implementation and identify barriers and facilitators. Thus, this proposal is of high-value, as it will provide randomized multicenter efficacy data while providing understanding for broad implementation following study end. For the effectiveness component, we will utilize a stepped-wedge cluster randomized design. Based on our preliminary data, the intraclass correlation coefficient is estimated around 0.5, an overall sample size of 60 episodes will be adequate to achieve powers greater than 90%. A potential pitfall of the stepped wedge design is the potential confounding effects of temporal trends. We will mitigate this by tracking data at the primary site, which will be in the sustain phase throughout the study entirety. We reduce temporal effects of site enrollment (e.g., staffing changes, temporal trends in hospital admissions) by enrolling sites at different times throughout the calendar year. The implementation component was designed utilizing the Practical, Robust Implementation and Sustainability Model (PRISM).\[2\] PRISM provides a scientifically rigorous and structured approach to implementation strategy development through domains focusing on (1) program, (2) external environment, (3) implementation and sustainability infrastructure and (4) recipients.\[2\] These elements are addressed as follows: Program. Organizational readiness across the study sites will be critical for success. Our proposal is based on evidence derived from a successful single-center study. The QI bundle is low-cost and all interventions are currently FDA-approved. Our innovative de-implementation of time-consuming, low-value workflows (e.g. IV medication administration) will decrease care complexity in the initial stages of SE treatment. The QI bundle components are trialable, adaptable and reversible. Treatment results are immediately observable by stakeholders through individual outcomes (SE cessation) and shared measure and feedback data reports. We highlight improved outcomes and safety as organizational, caregiver, and patient priorities to achieve broad buy-in. External Environment. Regulatory and professional organization priorities support our area of study and primary efficacy outcomes. Rapid treatment of SE has been identified as a quality measure by the AAN11, and guidelines for such care have been published by the AES.\[3\] Additionally, our study proposal further aligns with NAEC, which mandates a focus on rapid treatment of SE through pathway requirements across 260 hospitals. Data from our proposal will serve as a framework for accomplishing the goal of rapid SE treatment, which is inconsistently met at present.\[4\] Implementation and sustainability infrastructure. Our infrastructure will utilize proven features associated with successful implementation projects.\[5,6\] Co-investigators experienced in working within pSERG will provide a bridge to the local QI and clinical teams, engaging stakeholders at all 3 organizational levels (frontline staff, mid-level management and senior administration). Measure and feedback will be emphasized through control chart data and implementation reports. Furthermore, the adaptable protocol allows for site-specific implementation strategies for the QI bundle as well as iterative PDSA development in the Sustain and Independent phases in order to address local drivers. Recipients. Positive organizational characteristics are supported by LOS from senior hospital administrators and nurse managers. Furthermore, the co-investigators have previously collaborated with pSERG from their respective centers. Each site has access to data through Export, Transform, Load (ETL) data queries and EHR. The diverse demographics of patients is aided through intentional site selection and inclusion of nearly all ages of children. Importantly, our proposed interventions of performing basic seizure first aid and using non-IV forms of BZD aligns with those of patients and families in the ambulatory setting.\[7\]

Interventions

(1) standardizing BZD default to intranasal or buccal midazolam; (2) targeting initial BZD treatment within 10 minutes of seizure onset; (3) relocating and bundling all administration items needed to the hospital unit medication room; (4) utilizing basic seizure first aid in the initial patient assessment; (5) developing and implementing SE-specific EHR documentation; (6) multidisciplinary QI teams

OTHERQuality improvement bundle and local PDSA cycles with central support

Sites will implement both the standard QI bundle as well as site-specific PDSA cycles with central data and methods support.

OTHERQuality improvement bundle and local PDSA cycles without central support

Sites will implement both the standard QI bundle as well as site-specific PDSA cycles without central data or methods support.

Sponsors

Nationwide Children's Hospital
Lead SponsorOTHER
Children's Hospital of Philadelphia
CollaboratorOTHER
Boston Children's Hospital
CollaboratorOTHER
Children's National Research Institute
CollaboratorOTHER
Children's Hospital and Health System Foundation, Wisconsin
CollaboratorOTHER
UVA Children's Hospital
CollaboratorOTHER
Seattle Children's Hospital
CollaboratorOTHER
Phoenix Children's Hospital
CollaboratorOTHER
Emory University
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Participants will be masked as to whether the implementation bundle has been dissemination or implemented within the site they receive treatment.

Intervention model description

A stepped-wedge cluster randomized trial. This is a unidirectional crossover design in which clusters switch treatments at different time points, enabling statistically rigorous assessment of interventions while reducing ethical and resource limitations for quality improvement studies.

Eligibility

Sex/Gender
ALL
Age
30 Days to 18 Years
Healthy volunteers
No

Inclusion criteria

* SE episode occurs in a male or female child aged between \> 30 days to \< 19 years * Seizures meeting AT LEAST ONE of the following criteria: 1. continuous clinically apparent seizure lasting greater than 5 minutes 2. continuous clinically apparent seizure of any duration receiving BZD 3. repeated seizures without return to neurological baseline within 5 minutes

Exclusion criteria

* SE episode occurs in a child with infantile spasms * SE episode occurs in a child with electrographic-only seizures without clinical signs other than encephalopathy

Design outcomes

Primary

MeasureTime frameDescription
Time from the SE diagnosis to first dose of BZD30 daysTime in minutes from SE diagnosis to treatment with the first dose of a benzodiazepine (BZD) as measured during hospitalization, which will decrease chances of morbidity and mortality

Secondary

MeasureTime frameDescription
ICU transfer rate30 daysPercent of SE episodes resulting in transfer to the ICU within 6 hours of the episode as well as at any point during the admission.
Cost of hospitalization30 daysCost of hospitalization will be calculated as follows: cost per SE type x LOS
Change in PCPC score30 daysChange in PCPC score from admission to discharge

Countries

United States

Contacts

CONTACTAdam Ostendorf, MD
adam.ostendorf@nationwidechildrens.org614-722-5145
PRINCIPAL_INVESTIGATORAdam Ostendorf, MD

Nationwide Children's Hospital and The Ohio State University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026